Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Autor: Cascinu, Stefano, Rosati, Gerardo, Bilancia, Domenico, Nasti, Guglielmo, Iaffaioli, Rosario Vincenzo, Lonardi, Sara, Zagonel, Vittorina, Zaniboni, Alberto, Marchetti, Paolo, Romiti, Adriana, Leone, Francesco, Aglietta, Massimo, Giordano, Monica, Corsi, Domenico C., Ferraú, Francesco, Labianca, Roberto, Mosconi, Stefania, Ronzoni, Monica, Gianni, Luca, Rulli, Eliana, Poli, Davide, Galli, Francesca, Torri, Valter, De Simone, Irene, Galli, Fabio, Pasini, Felice, Rangoni, Giovanni, Venezia, Raffaele, Sozzi, Pietro, Nuzzo, Antonio, Berardi, Rossana, Frontini, Luciano, Rota, Silvia, Cozzi, Lorena, Scartozzi, Mario
Zdroj: In European Journal of Cancer September 2017 83:106-115
Databáze: ScienceDirect
Externí odkaz: